Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) PT at $20.25

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $18.56.

A number of research analysts have recently commented on IOVA shares. Piper Sandler dropped their target price on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a "neutral" rating for the company in a report on Friday, February 28th. The Goldman Sachs Group cut their target price on shares of Iovance Biotherapeutics from $22.00 to $19.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Chardan Capital lowered their price target on shares of Iovance Biotherapeutics from $34.00 to $30.00 and set a "buy" rating for the company in a report on Monday, March 3rd. HC Wainwright restated a "buy" rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a report on Friday, February 28th. Finally, Barclays decreased their price objective on Iovance Biotherapeutics from $22.00 to $5.00 and set an "overweight" rating for the company in a report on Monday.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of large investors have recently bought and sold shares of IOVA. AlphaQuest LLC grew its stake in shares of Iovance Biotherapeutics by 63.6% in the 4th quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company's stock valued at $34,000 after buying an additional 1,794 shares during the period. SBI Securities Co. Ltd. acquired a new position in Iovance Biotherapeutics during the 4th quarter worth approximately $36,000. GF Fund Management CO. LTD. bought a new position in Iovance Biotherapeutics in the fourth quarter worth approximately $47,000. One68 Global Capital LLC acquired a new stake in Iovance Biotherapeutics in the fourth quarter valued at approximately $74,000. Finally, Quarry LP bought a new stake in shares of Iovance Biotherapeutics during the fourth quarter valued at approximately $74,000. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Iovance Biotherapeutics Trading Down 2.8 %

Shares of Iovance Biotherapeutics stock traded down $0.09 during trading on Friday, hitting $2.99. 1,801,286 shares of the stock were exchanged, compared to its average volume of 7,405,795. The company has a fifty day moving average price of $4.04 and a 200-day moving average price of $6.89. The stock has a market capitalization of $978.71 million, a price-to-earnings ratio of -2.01 and a beta of 1.05. Iovance Biotherapeutics has a 1-year low of $2.70 and a 1-year high of $14.23.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, meeting the consensus estimate of ($0.26). The company had revenue of $73.69 million for the quarter, compared to the consensus estimate of $72.17 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. Equities research analysts forecast that Iovance Biotherapeutics will post -1.24 EPS for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.